These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12352896)

  • 1. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway.
    van Maurik A; Wood KJ; Jones ND
    Transplantation; 2002 Sep; 74(5):740-3. PubMed ID: 12352896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
    Liu H; Qiu F; Wang Y; Zeng Q; Liu C; Chen Y; Liang CL; Zhang Q; Han L; Dai Z
    Front Immunol; 2019; 10():306. PubMed ID: 30863408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependency of direct pathway CD4+ T cells on CD40-CD154 costimulation is determined by nature and microenvironment of primary contact with alloantigen.
    van Maurik A; Fazekas de St Groth B; Wood KJ; Jones ND
    J Immunol; 2004 Feb; 172(4):2163-70. PubMed ID: 14764682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway.
    Guo Z; Meng L; Kim O; Wang J; Hart J; He G; Alegre ML; Thistlethwaite JR; Pearson TC; Larsen CP; Newell KA
    Transplantation; 2001 May; 71(9):1351-4. PubMed ID: 11403253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
    Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
    J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8(+) T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination.
    Raisky O; Spriewald BM; Morrison KJ; Ensminger S; Mohieddine T; Obadia JF; Yacoub MH; Rose ML
    J Heart Lung Transplant; 2003 Feb; 22(2):177-83. PubMed ID: 12581766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement for donor and recipient CD40 expression in cardiac allograft rejection: induction of Th1 responses and influence of donor-derived dendritic cells.
    Nathan MJ; Mold JE; Wood SC; Csencsits K; Lu G; Eichwald EJ; Bishop DK
    J Immunol; 2004 Jun; 172(11):6626-33. PubMed ID: 15153477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway.
    Niimi M; Shirasugi N; Ikeda Y; Kan S; Takami H; Hamano K
    Transplantation; 2001 Nov; 72(9):1556-62. PubMed ID: 11707745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants.
    Qian Y; Dana MR
    Cornea; 2002 Aug; 21(6):592-7. PubMed ID: 12131037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection.
    Yuan X; Dong VM; Coito AJ; Waaga AM; Salama AD; Benjamin CD; Sayegh MH; Chandraker A
    Transplantation; 2002 Jun; 73(11):1736-42. PubMed ID: 12084995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
    Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
    Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.
    Zhai Y; Meng L; Busuttil RW; Sayegh MH; Kupiec-Weglinski JW
    J Immunol; 2003 Mar; 170(6):3024-8. PubMed ID: 12626556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of CD4 help in CD154 blockade-resistant memory CD8 T cell activation and allograft rejection in sensitized recipients.
    Wu Z; Wang Y; Gao F; Shen X; Zhai Y; Kupiec-Weglinski JW
    J Immunol; 2008 Jul; 181(2):1096-102. PubMed ID: 18606661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy.
    van Maurik Av; Herber M; Wood KJ; Jones ND
    J Immunol; 2002 Nov; 169(10):5401-4. PubMed ID: 12421913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade.
    Wang Y; Dai H; Liu Z; Cheng X; Tellides G; Dai Z
    Am J Transplant; 2006 Dec; 6(12):2851-60. PubMed ID: 17062001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways act as potent immunoregulatory cells in vitro and vivo.
    Cai Y; Zhou PJ; Tang XD
    Chin Med J (Engl); 2004 Aug; 117(8):1178-83. PubMed ID: 15361291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure.
    Xu H; Huang Y; Chilton PM; Hussain LR; Tanner MK; Yan J; Ildstad ST
    J Immunol; 2008 Nov; 181(9):6616-24. PubMed ID: 18941252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.
    Zhai Y; Meng L; Gao F; Busuttil RW; Kupiec-Weglinski JW
    J Immunol; 2002 Oct; 169(8):4667-73. PubMed ID: 12370407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.